Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School. He completed his residency in Surgery at The Milton S. Hershey Medical Center with additional year of training in Plastic and Reconstructive Surgery at Southern Illinois University. To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings. He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association. Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.

wound and hyperbaric research

Dr Ryan Moseley graduated from Swansea University with a BSc (Honours) Degree in Biochemistry. Later, he obtained his PhD from the School of Dentistry, University of Wales College of Medicine, examining the role of oxidative stress in periodontal disease. Dr Moseley continues his research at Cardiff University, where he is currently a Reader in Tissue Repair and Director of the CITER MSc Programme in Tissue Engineering. Dr. Moseley’s research focusses on the mechanisms underlying dermal and oral wound healing during health and disease; and the development of stem cell-, biomaterial- and pharmaceutical-based strategies to address impaired healing in these tissues.

Dermal, oral wound healing, stem cell-, biomaterial

After receiving his college education in Biology Major from Xinjiang University, People’s Republic of China, Dr. Li came to the US in 1985. He received MS degree in 1988 and PhD degree in 1991 from the Department of Developmental Biology and Cancer at the Albert Einstein College of Medicine, Bronx, New York City. Following a two-year post-doctoral/instructor fellowship with Dr. Joseph Schlessinger (Professor and Chairman, currently at Yale University Medical Center), he joined the faculty of the Ben May Institute for Cancer Research at the University of Chicago in the fall of 1993 as an Assistant Professor. He was recruited to University of Southern California (USC) Keck School of Medicine in 1999 and rose to full professor in 2006. He is currently a Professor and Director of the GMCB Graduate Program at USC Keck School of Medicine. His research interest focuses wound healing and cancer cell invasion. His laboratory is the first to identify the important role for the SECRETED form of heat shock protein-90 (Hsp90) in skin wound healing. He is the principle author of more than 80 peer-reviews publications in first-rate biomedical journals.

wound healing and cancer cell invasion

Jöns Hilborn is since 2001 the head of the Polymer Chemistry program at the Department of Materials Chemistry, Uppsala University in Sweden. He has extensive management experience from life science industry and co-ordination of European projects. His research interests are in the design, synthesis and preparation of polymers and specifically materials for tissue scaffolds and as delivery vehicles. Current focus is on injectable in-vivo gel forming matrices that acts on endogenous cells to regenerate and the development of RNAi to allow translation to therapies. Chemistry, biology, engineering is combined with medicine to bring basic research findings from the lab bench to the clinic and commercial applications. He served as president of “Tissue Engineering and Regenerative Medicine International Society” (TERMIS), which he was a part of creating. He currently serves as ERC panel chair, board member of the UK medical research council in regenerative medicine, associate editor, international advisor and the editorial board for a number of journals. He received his PhD from the Royal Institute of Technology in Stockholm, which was followed by seven years in industry before he joined the Swiss Federal Institute of Technology in Switzerland for eight years. He is a frequently invited speaker at international events and has published 200 scientific papers (h=46), 26 patent applications and has started 7 companies.

Design, synthesis and preparation of polymers and specifically materials for tissue scaffolds and as delivery vehicles

Dr Vickie R. Driver is a Fellow at the American College of Foot and Ankle Surgeons, licensed in Ma and RI and is board certified in foot surgery by the American Board of Podiatric Surgery. She has recently been nominated as Fellow, Royal College of Physicians and Surgeons-Glasgow, PM. Her career has a special emphasis on wound healing and limb preservation and she is an outspoken ambassador for progressive change in this field. Dr. Driver is a Professor of Surgery in the Department of Orthopedics at Brown University (Clinical). She has recently completed her tenure as president for the Advancement of Wound Care Association (AAWC), and has served for 9 years on the Board of Directors. She also proudly serves as a member of the Wound Healing Society (WHS) Board of Directors- member at large and chair-Industry relations and as member Board of Directors for the Critical Limb Ischemia (CLI) Global Society and chair wound healing committee. She has successfully chaired an initiative to expand the wound healing clinical endpoints considered by FDA. She proposed a combined effort between the WHS and AAWC to develop the Wound-care Experts/FDA-Clinical Endpoints Project [WEF-CEP] to strategically identify clinically meaningful, evidence-based and patient-centered wound care endpoints that are relevant for clinical research and trials. The goal is to collaboratively work with the FDA to expand the list of acceptable primary endpoints, recognizing that new and innovative treatments, devices and drugs may not have complete healing as the focus. Furthermore, validated endpoints other than complete healing will promote improved clinical trial design and will reduce the time for discoveries to reach our patients. Over the past three years, through ongoing interaction with the FDA InterCenter Wound Healing Work Group [ICWHWG], the WEF-CEP team has conducted a wide reaching Clinician Survey with 628 participating wound care experts, completed an extensive literature review for 28 wound care endpoints using the FDA criteria for a validated endpoint, published the clinical survey results in WRR, is in process to publish the research phase results and is currently conducting a Patient Survey to augment the findings of the Clinician Survey. Formal collaboration with the FDA established to execute on the WEF CEP work is on-going. As principle investigator, she has served on and initiated more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs. She has co-authored over 100 publications and abstracts. Dr. Driver is Director, Translational Medicine Wound Healing at Novartis Institute for BioMedical Research. She is dedicated to making a scientific contribution to both the understanding of the natural history of disease and the discovery of new therapies and diagnostics to advance the treatment of patients who suffer with wounds and are at risk of limb loss. .

wound healing and limb preservation

Ms. Kirkland-Walsh received her NP degree as a Family/Geriatric Nurse Practitioner from the University of California, Davis, her BSN and MSN degrees from Cal State, Sacramento, and a WOCN certification from the University of Washington, Seattle. She has served as Nurse Manager in the Medical Surgical Unit / Geriatrics and as Diabetes Educator and Clinical Trials Nurse in Waterford, Ireland, as a Palliative Care Nurse at Kaiser, and as Cardiology Nurse Practitioner at UCDMC. She Completed her PhD in Nursing at the University of California San Francisco. Since 2004, Ms. Kirkland-Walsh has been a board member for the Sacramento Community Clinics Consortium. She presently serves as an Urgent Care Nurse Practitioner at Kaiser, as Assistant Medical Director at The Effort Indigent Health Clinic, and as Wound Care Nurse Practitioner at University of California, Davis Health System in Sacramento, CA. In the latter role, she leads a multidisciplinary team that focuses on the prevention and treatment of chronic wounds. In addition to these various positions, Ms. Kirkland-Walsh has worked with geriatric patients in Ireland, Great Britain, and, most recently, in Haiti where she did disaster relief work as a volunteer for Medishare and served as Chief Medical Officer at the Bernard Mevs Hospital, the only acute care hospital in Haiti. She also comes with prior teaching experience, serving as clinical faculty for Nurse Practitioner programs at University of California, Davis, University of California, San Francisco, Sonoma State, University of Phoenix, and Samuel Merritt. Her proposed area of research focuses on perfusion related pressure ulcers and the comparison on hospital acquired pressure ulcers to community acquired pressure ulcers.

Ulcers, Wound Care,Skin

Naiem Moiemen, MB BS, MSc, FRCS (Plast) is an Honorary Professor at the University of Birmingham and a consultant plastic and burns surgeon at University Hospital Birmingham. He is Director of the Scar Free Foundation Centre for Burn Research in Birmingham He is the Clinical Lead of the Midland Burns Care Network, serving a population of 10 million. Naiem is Immediate Past President of European Burn Association Executive, President-Elect of the International Association of Burn Injury (ISBI) and past Chairman of the British Burn Association (BBA). He is supervising 3 PhD students and current chief investigator of 4 current multi-centre burns clinical trials: NIHR-HTA pressure garment pilot efficacy multi-centre trial, and the SIFTI trial investigating the acute response to burn injury and HESTIA trial investigating gut translocation following thermal injury. He is also PI on the Wellcome-NIHR HICF to develop an anti-scarring wound dressing, and recently £4.5m Libor Grant fund to establish a scar and wound healing research centre in Birmingham. He has published more than 90 papers in peer review journals and book chapters. He is a senior editor of BURNS journal and deputy editor of Journal of Burn and Trauma.

Scars, Wound Healing, Burns, Burn Injury

Dr. Thomas E. Serena MD FACS, Founder and Medical Director of SerenaGroup™, a family of wound, hyperbaric and research companies. Dr. Serena completed his residency in Surgery at the Hershey Medical Center. To date he has opened and operates wound care centers across the United Sates and globally. He has been the lead or Principal investigator in over 100 clinical trials and is recognized internationally as an expert in the field of wound healing: He has more than 100 published papers and has given more than 1000 invited lectures throughout the world. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.

• Hyperbaric Oxygen therapy in the treatment of any of the 14 approved indications • Amputation prevention • the business of wound care • Research in wound healing • Diagnostics in wound healing • Indocyanine Green Fluorescent Angiography in wound healing • Advanced wound care

Jasmina Begic finished postgraduate study on the Sarajevo University Medical School of Medicine. She is Medical Consultant for BIOPTRON, Zepter Internastional for Bosnia and Herzegovina , Founder of Association for Wound management in B&H, Founder and author of Euro-Asian Forum, one of founder of www.BALWMA.org. She is member of EWMA Cooperating Organisations Board.

Wound Management, Wound Healing, Advance wound treatments

Michael Cioroiou is a board-certified general surgeon with more than 35 years of experience. He specializes in wound care as well as breast diseases. He have a caring and understanding nature and aim to answer all patient’s questions and concerns in order to make office visits as pleasant and professional as possible. He have been named as one of Castle Connolly’s Top Doctors in the New York Metro Area every year since 2002, and in 2011, he received a Patients Choice Award from users of the medical provider review Website Vitals.

Healthcare Management, Surgery, Clinical research, Patient safety.

Denis Barritault graduated in Math and Physics, completed his Ph.D. in biochemistry in Paris University. Post doctoral in molecular immunology at Pasteur Institute and NYU as NIH Fogarty Fellow he joined INSERM unit in Paris as developmental biologist. He made the first description and patents of FGF extracted from retina in 1979 and 82 as skin and cornea healing agent, became full professor at Paris East University in 1985, founded and directed a CNRS Laboratory on cell and tissue regeneration until 2003. He is now President of OTR3, Emeritus Professor and author in over 200 publications and 29 patents.

Tissue regeneration, Molecular immunology.

Joel E Michalek completed his PhD from Wayne State University. He has a broad background in biostatistics pertaining to theory and methods, preclinical and clinical trials, and epidemiology. He has written protocols and grants, analyzed data, and co-authored manuscripts arising from clinical studies in surgery, emergency medicine, cancer, and pediatrics and was formerly Principal Investigator of the Air Force Health Study, a 20-year prospective epidemiological study of veterans who sprayed Agent Orange and other herbicides in Vietnam. He has authored 180 journal articles and two book chapters.

Cancer Therapy, Signal Processing in Clinical Medicine and Genomics.

Dr. Efraim Jaul is a specialist in Family Medicine and Geriatric Medicine. He is the Head of the Geriatric Skilled Nursing Department at the Sarah Herzog Hospital, Jerusalem, Israel. It is affiliated with the Hebrew University-Hadassah Medical School, Jerusalem. He is a Clinical Senior Lecturer in the Hebrew Medical School Faculty. He teaches medical students as well as nursing students at the Academic Nursing schools of Hadassah Hospital (Jerusalem), Kaplan Hospital (Rechovot), Ichilov Hospital (Tel Aviv), and Jerusalem College of Technology (Jerusalem). He supervises clinical practice and mentors students. He developed and established a pioneering inpatient unit at the Herzog Hospital specifically for the treatment of pressure ulcers concerning the need for a special unit and the resulting benefits for the immobile elderly patients. This unit has elicited interest in serving as a model for geriatric treatment facilities around the world and has set the standard for developing specialized pressure ulcer units. He published 44 scientific papers in national and international journals and five books on aging.

Pressure Ulcers, Wound healing, Advanced dementia.

Sandeep Shrivastava is from India Born in 1968, he took over as DEAN at the age of 42 years. He did his graduation and post-graduation from G. R Medical College, Gwalior, India. He is an Orthopedic Surgeon, with expertise in Limb deformity correction and reconstruction. He have published 2 books, 55 papers, 62 International papers and 6 copyrights/patents on ranging interests from Education to Bio- Informatics. His innovations include a Safety App-Pre-Yell; a research tool - H_COIN; a learning methodology- “Self Assertive Learning”, and an education quality management program-“Academic Appraisal Program”. He is a developer for “STARS therapy” for wound healing. He has travelled extensively through all the continents and delivered talk on various aspects of this research project .This is an attempt to find an ideal solution for millions who continue to suffer from complex wounds.

Wound Healing, Regenerative Medicine, Wound Management.

Dr. Thomas E. Serena MD FACS, Founder and Medical Director of SerenaGroup™, a family of wound, hyperbaric and research companies. Dr. Serena completed his residency in Surgery at the Hershey Medical Center. To date he has opened and operates wound care centers across the United Sates and globally. He has been the lead or Principal investigator in over 100 clinical trials and is recognized internationally as an expert in the field of wound healing: He has more than 100 published papers and has given more than 1000 invited lectures throughout the world. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association

• Hyperbaric Oxygen therapy in the treatment of any of the 14 approved indications • Amputation prevention • The business of wound care • Research in wound healing • Diagnostics in wound healing • Indocyanine Green Fluorescent Angiography in wound healing • Advanced wound care

Dr. Gerlach was recruited to the University of Pittsburgh after the Washington-based non-profit World Technology Evaluation Center (WTEC) report, “Tissue Engineering and Research 2002", identified him as one of the experts worldwide addressing 3-D perfusion high-density culture design for medical devices. Dr. Gerlach holds an MD and two PhDs with a background in surgery, experimental surgery, and bioengineering. With his dual appointment, he directs the interdisciplinary Bioreactor Group at the McGowan Institute for Regenerative Medicine within the University of Pittsburgh and contributes to the Schools of Medicine and Engineering. Most of his projects focus on cell biology methodology and bioengineering technology developments are designed to contribute to knowledge on controlling cell behavior for anticipated patient treatments. His working hypotheses, consequently, relates mostly to the behavior and function of progenitor cells in an in vitro environments that he developed. Dr. Gerlach´s general interest is in technologies for the clinical translation of stem cell biology research, and he concentrates on the development of innovative cell-based therapies. In the area of skin he developing active wound dressings and cell spray grafting technologies. His “Skin Gun” development was broadcasted on National Geographic TV and is posted on YouTube under the key word “skin gun”.

Dr.Gerlach's research focus is on improving the understanding of how to control the expansion and differentiation of stem cells on a clinical translation scale. Organs and cells of interest have been skin, liver, bone marrow and hematopoietic, neuronal, adipose tissue, and cancer cells. He works with adult progenitors, fetal tissue derived progenitors, and embryonal stem cell lines. He specializes in advancing 2-D in vitro culture models to 3-D perfusion high-density cell-co-culture systems for stem cells, development of bioreactors for organ support, and systems for the production of cells for regenerative medicine cell transplantation. General topics include maintenance and differentiation of cells in vitro for extracorporeal, temporary clinical use as a hybrid organ, in vitro models for studies on stem cell niche interactions, and production of cells in cell-based therapy.

Brian Peskin, BSEE-MIT (1979), is a theoretical research scientist specializing in lipids‐based pharmacognosy, and CEO of Peskin Pharmaceuticals. His research focuses specifically on physiologically targeted essential fatty acids (EFAs) and their eicosanoid metabolites. Being a translational science expert with a long-term interest in diabetes and its underlying pathophysiology, extensive work in oncology and cardiology preceeded his applications into diabetic foot ulcers. His work is focused on pathways maximizing oxygen delivery and blood flow to the human cell and maximizing tissue functionality. Focus is on supporting and optimizing the patient's natural physiologic processes—not blocking or impeding metabolic pathways.

His research focuses specifically on physiologically targeted essential fatty acids (EFAs) and their eicosanoid metabolites. Being a translational science expert with a long-term interest in diabetes and its underlying pathophysiology, extensive work in oncology and cardiology preceeded his applications into diabetic foot ulcers/wounds.

Dr. Chaur-Dong Hsu received his medical degree from Kaohsiung Medical School in Kaohsiung, Taiwan, in 1982, and his master of public health degree from The John Hopkins University School of Hygiene and Public Health in Baltimore, MD., in 1991. Currently, he is Chairman and Frank P. Iacobell Endowed Professor of Department of Obstetrics and Gynecology, Wayne State University School of Medicine; Program Director and Principal Investigator of Women’s Reproductive Health Research Career Development, National Institutes of Health (NIH); Specialist-in-Chief, OB/GYN, Hutzel Women's Hospital/Detroit Medical Center and Chief of OB/GYN at Barbara Ann Karmano Cancer Institute.

Obstetrics and Gynecology, Surgical site Infection control, Maternal-Fetal Medicine,Hygiene and Public Health

Born in Los Angeles, Ronald Sherman earned his BS in Entomology at UC Riverside, his MD at UCLA, and his Masters degree in Clinical Tropical Medicine at the University of London, School of Hygiene and Tropical Medicine. He completed his Internship at Mt. Zion Hospital & Medical Center (one of the UC San Francisco training hospitals) in 1984, his Internal Medicine Residency at UC Davis in 1987 and his Infectious Diseases Fellowship at UC Irvine in 1991. Dr. Sherman started studying myiasis and maggot therapy during medical school, published his first paper on the topic in 1983, and started the first prospective studies in 1990. Twenty years ago, Dr. Sherman published his laboratory methods, so that maggot laboratories could develop throughout the world and supply local populations with medicinal maggots. There are now approximately 22 independent laboratories around the world producing medicinal maggots. After 4 years working for the Veterans Affairs Medical Center (Long Beach, CA) as an infectious diseases and geriatrics specialist, Dr. Sherman joined the faculty of the University of California in 1995, where he continued his research in myiasis and maggot therapy. Requests for Dr. Sherman’s medical grade maggots increased world-wide, and in 2004, after review of Dr. Sherman’s clinical studies, the FDA granted full marketing clearance for his Medical Maggots. In order to comply with the high manufacturing standards of the FDA, the laboratory (now known as Monarch Labs) separated from the University in 2005, and Dr. Sherman left the University himself in 2008 to oversee that laboratory, and to continue directing the BioTherapeutics, Education & Research (BTER) Foundation, a non-profit, member-supported organization dedicated to advancing health care through education and research in the therapeutic use of living animals. To minimize conflicts of interest, Dr. Sherman does not accept salary for his work for Monarch Labs nor the BTER Foundation, and he donates all speaking honoraria to the Foundation. To support his family, Dr. Sherman works 1 - 2 days/week as an HIV / AIDS Specialist for the Orange County health department.

Maggot therapy, Leech therapy, and the many other Biotherapeutic modalities

Dr. Efraim Jaul is a specialist in Family Medicine and Geriatric Medicine. He is the Head of the Geriatric Skilled Nursing Department at the Sarah Herzog Hospital, Jerusalem, Israel. It is affiliated with the Hebrew University-Hadassah Medical School, Jerusalem. He is a Clinical Senior Lecturer in the Hebrew Medical School Faculty. He teaches medical students as well as nursing students at the Academic Nursing schools of Hadassah Hospital (Jerusalem), Kaplan Hospital (Rechovot), Ichilov Hospital (Tel Aviv), and Jerusalem College of Technology (Jerusalem). He supervises clinical practice and mentors students. He developed and established a pioneering inpatient unit at the Herzog Hospital specifically for the treatment of pressure ulcers concerning the need for a special unit and the resulting benefits for the immobile elderly patients. This unit has elicited interest in serving as a model for geriatric treatment facilities around the world and has set the standard for developing specialized pressure ulcer units.

The primary concept behind the pressure ulcers is the idea that pressure ulcers do not occur alone, and are an integral part of the clinical assessment and preventive treatment of the geriatric patient became a guiding principle in all of his work. It is important to attend not only to the pressure ulcers but also the general needs of the patient. This approach was summarized by Dr. Jaul in an article entitled "Non-Healing Wounds The Geriatric Approach" and a review article about " Assessment and Management of Pressure Ulcers in the Elderly Patients Current Strategy ". This leading essay highlights multi-factorial risks and treatment involved in Multidisciplinary and Comprehensive Approaches to Optimal Management of Pressure Ulcers in the Elderly. Dr. Jaul coined a new terminology in the field of pressure ulcers "atypical pressure ulcers", based on location and etiology classified medical devices, bone deformation and severe spasticity. He was a stream planner for the scientific program of Pressure Ulcers in the 4th Congress of World Union Wound Healing Societies (WUWHS 2012) in Yokohama, Japan. Currently, he is investigating comorbidities focusing on advanced dementia and other comorbidity on pressure ulcers to understand the underlying pathogenesis

Dr. Angela Peghetti is the A.I.S.LE.C. President. She performs coordinative and organisational tasks within different fields: scientific committees, administrative office organizations, institutions and media. In collaboration with the relevant bodies, she draws up projects, deals with paperwork, budget and balance sheets for the same Society. She is Professor and lecturer in the Tor Vergata University of Roma and Bicocca University of Milano. She works in Solatrix hospital in Rovereto (Italy) and focuses on developing Education, Research, Data Collection, alongside organising the research and updating of practice recommendations in the field of wound care.

wound care, biofilms in clinical practice

Dr nidal Younes has completed his MD from Jordan University and postdoctoral studies at the University of Chicago School of Medicine. He is the director of foot clinic at the national center for diabetes, endocrine and genetics, an endocrine surgeon at the JUH.

Diabetic Foot Ulcers, Endocrinology and Genetics

Dr Hamilton completed his PhD in Cellular Engineering at the University of Glasgow in 2000. He worked as a Research Scientist with Advanced Medical Solutions PLC., in England, followed by Postdoctoral studies at the McGowan Institute for Regenerative Medicine, University of Pittsburgh and at the University of British Columbia, Vancouver. He established his independent laboratory at the University of Western Ontario in 2007, which is focused on biomaterials and connective tissue repair. He has published 39 original research articles, and serves as an editorial board member for the Journal of Cell Communication & Signaling and The Journal of Cytology & Histology

Non-healing skin wounds, Wound Therapy and Wound Management

Onnen Grauhan is professor of cardiovascular surgery at the Charite`, Humboldt University Berlin and consultant surgeon at the Department of Cardiothoracic and Vascular Surgery at Deutsches Herzzentrum Berlin, Germany.

Cardiovascular surgery, Wound mannagement, Nagative pressire therapy

Michele (Shelly) Burdette-Taylor has completed her PhD at the University of San Diego in California. She is an assistant professor at the University of Alaska Anchorage. She teaches undergraduate and graduate courses in community health, foot care, and wound care for the college of health, school of nursing and physician assistant program. She has published numerous skin, wound, pressure ulcer, and foot care articles. Her most recent publication was a chapter for the new Wound Ostomy Continence Nurses Core Curriculum for Wound Care for entitled Foot and Nail Care.

Lower extremity wounds

Mieczyslawa Franczyk has completed her master's degree in PT and post graduated study for PhD from University of Physical Education in Poland. She graduated from University of Illinois Public School of Health. She is a member of American Physical Therapy Association. She is author or co-author 8 papers, 7 in arena of subatmospheric pressure wound therapy

Subatmospheric pressure wound therapy , Fistulae management, Wound Mangement and Therapy

Jasmina Begic finished postgraduate study on the Sarajevo University Medical School of Medicine. She is Medical Consultant for BIOPTRON, Zepter Internastional for Bosnia and Herzegovina , Founder of Association for Wound management in B&H, Founder and author of Euro-Asian Forum, one of founder of www.BALWMA.org. She is member of EWMA Cooperating Organisations Board.

Wound Management, Wound Healing, Advance wound treatments